We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
C4x Discovery Holdings Plc | LSE:C4XD | London | Ordinary Share | GB00BQQ2RV18 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 12.00 | 10.30 | 10.80 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 1.71M | -11.11M | -0.0441 | -2.72 | 30.27M |
Date | Subject | Author | Discuss |
---|---|---|---|
03/1/2024 09:39 | thanks - aconic - I only picked this up from RNS this morning but looks very overlooked at £30m market cap. | nigelpm | |
03/1/2024 09:35 | Runway was already to Dec 24 and now extended to around Sept 2025, even without any further milestone payments or a sale of the non-core Malt-1 asset (both of which are expected). Mcap now 30m. Morphic whose only asset is in the same space as ONE of C4XD's (and looking inferior in phase 1 trials due to the worryingly high dose required) has a market cap of $1.44 billion. This has been floating under the radar for far too long. Firestarter clearly short and desperately hoping to close the position at less of a loss. All (unwarranted) funding worries now pushed out to rediculous time horizons and CD has already said that it's entirely possible that the company is now self financing. There's really no reason for this not to fly much higher after the initial wave of profit taking. | 1aconic | |
03/1/2024 09:13 | 10p by close | firestarter1 | |
03/1/2024 09:13 | I asume C4X may pay a great dividend in the future. | luckyabbeygale | |
03/1/2024 09:07 | Many spiked in over 14p Now time to dive to 10 | firestarter1 | |
03/1/2024 09:02 | Nigel, Firestarter does this on so many shares in the news......all BS of course, best ignored. He will go plague another share tomorrow. | intoodeep | |
03/1/2024 09:01 | HZM VAST and this one are the best to be in. | luckyabbeygale | |
03/1/2024 09:01 | Shorts increased by 6% Hence why it is not risingIf shorts were closing there would be more buying | firestarter1 | |
03/1/2024 09:00 | Looking weak and nt to sell | firestarter1 | |
03/1/2024 08:55 | Firestarter filtered - absolute nutcase. | nigelpm | |
03/1/2024 08:54 | Firestarter who do you work for? | intoodeep | |
03/1/2024 08:48 | Time to add. Buyers was paying 15p first thing. | luckyabbeygale | |
03/1/2024 08:46 | In for some more at 12.7p. | luckyabbeygale | |
03/1/2024 08:46 | No one talking bout it wirher | firestarter1 | |
03/1/2024 08:46 | Notninterest | firestarter1 | |
03/1/2024 08:45 | All folks spiked in | firestarter1 | |
03/1/2024 08:45 | Dumping hard | firestarter1 | |
03/1/2024 08:45 | 22million mkt cap according to advfn | p@ | |
03/1/2024 08:42 | Wow - incredible stuff here - market cap of £32m but c. £20m in bank with no debt and many opportunities to generate cash. | nigelpm | |
03/1/2024 08:42 | Drug discovery company C4X Discovery said it has received a milestone payment of USD11 million from FTSE 100-listed pharmaceutical firm AstraZeneca, triggered by pre-clinical progress of C4X Discovery's NFT2 Activator programme. AstraZeneca is developing C4X Discovery's former programme to deliver an oral therapy for the treatment of inflammatory and respiratory diseases, with a lead focus on chronic respiratory disease. As announced under the terms of the licencing agreement in November 2022, C4X Discovery received an initial USD2 million upfront payment from AstraZeneca and is potentially entitled to receive up to USD400 million in preclinical, clinical development and commercial milestones, as well as tiered mid-single digit royalties on future sales. C4X Discovery Clive Dix commented: "This significant preclinical milestone payment marks the progress AstraZeneca has made in driving the NRF2 Activator programme forward. NRF2 is a challenging target and this achievement provides further validation of our ability to generate differentiated, quality molecules in immuno-inflammation. | p@ | |
03/1/2024 08:36 | Good morning All UK shares investing seems risky at present certainly those on AIM but I'm in at 12p DYOR! | maytrees |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions